Upstate New York Hematology & Hematologic Oncology Conference: Updates from the 65th ASH Annual Meeting

Niagara Falls, NY US
March 16, 2024 to March 17, 2024

This CME-accredited activity, the Upstate New York Hematology & Hematologic Oncology Conference: Updates from the 65th ASH Annual Meeting, is a two-day symposium designed to provide an engaging and interactive forum for discussing the latest breakthroughs in benign and malignant hematology. The conference will feature lectures and panel discussions by regional experts from the Upstate New York region and invited nationally recognized experts from leading institutions across the United States. This symposium will offer in-depth coverage of the entire spectrum of malignant hematology topics, including lymphoid, myeloid, and plasma cell neoplasms, as well as benign hematology topics and considerations for special populations. This activity aims to improve knowledge and advance the ability of hematology oncology providers to apply current and emerging treatment strategies in managing benign and malignant blood disorders to improve patient outcomes.

Expert faculty will contextualize potentially practice-changing research, including the abstracts presented at the 65th ASH Annual Meeting in December 2023 (ASH23), and discuss how the results may alter the current standard of care. This conference will emphasize a multidisciplinary approach and the integration of new advances into patient-centered care.

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

Organizing Committee 

Course Director:

Binay Shah, MD, MHA Binaytara Foundation

Co-Chairs:

Francisco J. Hernandez-Ilizaliturri, MD - Roswell Park Comprehensive Cancer Center

Matthew J. Cortese, MD, MPH - Roswell Park Comprehensive Cancer Center

Venue Information 

The conference will be held at the Niagara Falls Convention Center, 101 Old Falls Street, Niagara Falls, NY 14303.

If you are attending this meeting and need to reserve a hotel room, please reserve your room at the Sheraton Niagara Falls (across the street from the Niagara Falls Convention Center) using the link below to take advantage of the discounted group rate of $109 per night plus applicable taxes and fees:

https://sheratonatthefalls.com/group/binaytaraoncologyconferencemarch2024

Learning Objectives

  1.  Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care for patients with blood disorders and hematologic malignancies.
  2.  Choose new therapeutic options for the treatment of benign and malignant hematologic disorders, understanding appropriate indications, and contraindications to these therapeutic approaches.
  3. Integrate evolving diagnostic, prognostic, and therapeutic approaches to the management of patients with blood disorders and hematologic malignancies.
  4.  Describe the approved cellular therapies for patients with hematologic malignancies, including updated efficacy and toxicity data, and identify patients who should be referred for CAR T-cell therapies.
  5. Identify and manage side effects of therapies used to treat benign and malignant hematologic disorders.

Global Oncology Project

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 14.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 14.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 14.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 14.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 14.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 14.50 Contact Hours.
Course opens: 
11/30/2023
Course expires: 
03/30/2024
Event starts: 
03/16/2024 - 8:00am PDT
Event ends: 
03/17/2024 - 4:40pm PDT
Cost:
$350.00

DAY 1 - March 16th, 2024

All times are listed in Eastern Time (ET)

07:00 – 08:00 AM: Breakfast and Exhibits


08:00 – 08:10 AM: Introduction

08:10 – 08:25 AM: BTF's Efforts to Improve Access to Cancer Care


08:25 – 10:10 AM: Session I: Non-Hodgkin's B-Cell Lymphomas

Moderator: Francisco J. Hernandez-Ilizaliturri, MD

08:25 – 08:30 AM: Case Presentation - Francisco J. Hernandez-Ilizaliturri, MD

08:30 – 08:55 AM: Clinical Practice Changes in the Front-line Management of DLBCL & HGBL - Kieron M. Dunleavy, MD

08:55 – 09:20 AM: Clinical Practice Changes in the Management of Fit (Transplant-Eligible) Patients with Relapsed/Refractory (R/R) DLBCL & HGBL - Jeremy Abramson, MD

09:20 – 09:45 AM: Clinical Practice Changes in the Management of Elderly or Frail (Transplant-Ineligible) Patients with Relapsed/Refractory (R/R) DLBCL & HGBL - Paolo Caimi, MD

09:45 – 10:10 AM: Interactive Round Table on DLBCL/HGBLs


10:10 – 10:20 AM: Break and Exhibits


10:20 AM – 12:25 PM: Session II: Non-Hodgkin B-Cell Lymphomas

Moderator: Francisco J. Hernandez-Ilizaliturri, MD

10:20 – 10:25 AM: Case Presentation (Mantle Cell Lymphoma) - Francisco J. Hernandez-Ilizaliturri, MD

10:25 – 10:50 AM: Clinical Practice Changes in the Front-line Management of Mantle Cell Lymphoma (MCL) - Francisco J. Hernandez-Ilizaliturri, MD

10:50 – 11:15 AM: Clinical Practice Changes in the Management of Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) - Julio Chavez, MD, MS

11:15 – 11:40 AM: Clinical Practice Changes in the Front-line Management of Follicular Lymphoma (FL) - Dorothy Pan, MD

11:40 AM – 12:05 PM: Clinical Practice Changes in the Management of Relapsed/Refractory Follicular Lymphoma - Francisco J. Hernandez-Ilizaliturri, MD

12:05 – 12:25 PM: Interactive Round Table on MCL and FL


12:25 – 01:25 PM: Lunch and Exhibits


01:25 PM – 03:15 PM: Session III: Non-Hodgkin’s Lymphoma

Moderator: Francisco J. Hernandez-Ilizaliturri, MD

01:25 – 01:30 PM: Case Presentation (Low-Grade Lymphoma (MZL)) - Francisco J. Hernandez-Ilizaliturri, MD

01:30 – 01:55 PM: Clinical Practice Changes in the Management of Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia (LPL/WM) and Marginal Zone Lymphoma (MZL) - Narendranath Epperla, MD, MS

01:55 – 02:00 PM: Case Presentation (T-cell lymphoma) - Francisco J. Hernandez-Ilizaliturri, MD

02:00 – 02:25 PM: Clinical Practice Changes in the Management of Systemic and Cutaneous T-Cell Lymphomas (CTCLs) - Francine M. Foss, MD

02:25 – 02:50 PM: Clinical Practice Changes in the Management of Systemic and Peripheral T-Cell Lymphomas - Grant Schofield, MD

02:50 – 03:15 PM: Interactive Round Table


03:15 – 03:35 PM: Break and Exhibits


03:35 – 04:55 PM: Session IV: Bone Marrow Transplant and Cellular Therapy

Moderator: Marco Davila MD, PhD

03:35 – 03:40 PM: Case Presentation (R/R ALL with Referral to CAR T-Cell Therapy) - Marco Davila MD, PhD

03:40 – 04:05 PM: Updates in Cellular Therapy: Beyond CD19 and BCMA - Catherine Bollard, MBChB, MD

04:05 – 04:30 PM: Updates in Bone Marrow Transplantation - Shernan Holtan, MD

04:30 – 04:55 PM: Interactive Panel Discussion


04:55 – 05:00 PM: Closing Remarks

 

DAY 2 - March 17th, 2024

All times are listed in Eastern Time (ET)

07:00 – 08:00 AM: Breakfast and Exhibits


08:00 – 08:05 AM: Welcome


08:05 – 10:15 AM: Session V: Leukemia and Myelodysplastic Disorders

Moderator: Eunice Wang, MD

08:05 – 08:10 AM: Case Presentation - Eunice Wang, MD

08:10 – 08:35 AM: Clinical Practice Changes in the Management of Acute Lymphoblastic Leukemia (ALL) and Acute Lymphoblastic Lymphoma (LBL)

08:35 – 09:00 AM: Clinical Practice Updates for Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPNs) - Steven Green, MD

09:00 – 09:25 AM: An Update on Myelodysplastic Syndromes and Clonal Cytopenias - Elizabeth Griffiths, MD

09:25 – 09:50 AM: Clinical Practice Updates for Acute Myeloid Leukemias (AML) - Hetty Carraway, MD, MBA

09:50 – 10:15 AM: Interactive Round Table


10:15 – 10:35 AM: Break and Exhibits


10:35 AM – 12:10 PM: Session VI: CLL and Geriatric Hematology

Moderator: Desi Carozza MD, FAAHPM

10:35 – 10:40 AM: Case Presentation - Desi Carozza MD, FAAHPM

10:40 – 11:05 AM: Clinical Practice Changes For the Initial/Front-line Management of Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL), Hairy Cell Leukemia (HCL), and Richter Transformation (RT) - Nicole Lamanna, MD

11:05 – 11:30 AM: The Evolving Treatment Landscape of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL), Hairy Cell Leukemia (HCL) and Richter Transformation - Matthew Cortese, MD, MPH

11:30 – 11:55 AM: Considerations for Older Adults with Hematologic Malignancies - Pallawi Torka, MD

11:55 AM – 12:10 PM: Interactive Round Table


12:10 – 01:15 PM: Lunch and Exhibits


01:15 – 03:00 PM: Session VII: Hodgkin’s Lymphoma and AYA

Moderator: Matthew Cortese, MD, MPH

01:15 – 01:20 PM: Case Presentation (Classical Hodgkin Lymphoma in an AYA patient) - Matthew Cortese, MD, MPH

01:20 – 01:45 PM: Clinical Practice Changes in Hodgkin Lymphoma - Alex Niu, MD

01:45 – 02:10 PM: Behavioral Changes and Stress Reduction Strategies in Young Patients with HL - David S. Kroll, MD

02:10 – 02:35 PM: Adolescent and Young Adult (AYA) Considerations for Hematologic Oncologists - Kara M. Kelly, MD

02:35 – 03:00 PM: Interactive Round Table


03:00 – 03:35 PM: Session VIII: Multiple Myeloma & Plasma Cell Neoplasms

Moderator: Jens Hillengass, MD, PhD

03:00 – 03:05 PM: Case Presentation - Jens Hillengass, MD, PhD

03:05 – 03:30 PM: Clinical Practice Updates of Multiple Myeloma - Hamza Hassan, MD

03:30 – 03:55 PM: Clinical Practice Updates of Amyloidosis, MGUS, and Other Plasma Cell Disorders - Ehsan Malek, MD

03:55 – 04:20 PM: Interactive Panel Discussion


04:20 – 04:30 PM: Break and Exhibits


04:30 – 05:20 PM: Session IX: Benign Hematology

Moderator: Elizabeth Griffiths, MD

04:30 – 04:55 PM: Clinical Practice Updates in Benign Hematology

04:55 – 05:20 PM: Thrombosis Risk and Prevention for Patients with Cancer - Alok Khorana, MD


05:20 – 05:30 PM: Adjourn
 

Niagara Falls Convention Center
101 Old Falls Street
Niagara Falls, NY 14303
United States

If you are attending this meeting and need to reserve a hotel room, please reserve your room at the Sheraton Niagara Falls (across the street from the Niagara Falls Convention Center) using the link below to take advantage of the discounted group rate of $109 per night plus applicable taxes and fees:

https://sheratonatthefalls.com/group/binaytaraoncologyconferencemarch2024

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Chair(s)

Matthew Cortese, MD, MPH

has a financial relationship (Professional Services) with Abbvie, Inc.;.
has a financial relationship (Professional Services) with Secura Bio, Inc;.
has a financial relationship (Professional Services) with Precision Oncology;.
has a financial relationship (Professional Services) with Curio Life Sciences;.
has a financial relationship (Professional Services) with ADC Therapeutics, Inc;.
has a financial relationship (Professional Services) with Synthekine;.
has a financial relationship (Professional Services) with Astra Zeneca, Inc;.
has a financial relationship (Professional Services) with Cellectar Biosciences;.

Francisco Hernandez-Ilizaliturri, MD

has a financial relationship (Professional Services) with BioGene;.
has a financial relationship (Professional Services) with Cellectar;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with BMS/Celgene;.
has a financial relationship (Professional Services) with Incyte/Morphosys;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with ADC Therapuetics;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Epyzine;.
has a financial relationship (Professional Services) with Novartis;.
Session Chair(s)

Jens Hillengass, MD, PhD

has a financial relationship (Independent contractor) with Angitia;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Independent contractor) with Targeted Oncology;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with Sebia;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Prothena;.
Speaker/Topic Presenter(s)

Jeremy Abramson, MD, MMSc

has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Interius;.
has a financial relationship (Independent contractor) with Cellectar;.
has a financial relationship (Independent contractor) with Seagen;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Independent contractor) with Gilead;.
has a financial relationship (Independent contractor) with BeiGene;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with AbbVie;.

Catherine Bollard, MBChB, MD

has a financial relationship (Stock) with Neximmune and Repertoire Immune Medicines;.
has a financial relationship (Stock Options) with Mana Therapeutics;.
has a financial relationship (Stock Options) with Catamaran Bio;.
has a financial relationship (Independent contractor) with SOBI;.
has a financial relationship (Stock Options) with Cabaletta Bio;.
has a financial relationship (Stock Options) with Minovia TX Ltd;.

Paolo Caimi, MD

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Arvinas;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Recordati Rare Diseases;.

Hetty Carraway, MD, MBA

has a financial relationship (Professional Services) with Jazz;.
has a financial relationship (Professional Services) with Agios;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Syndax;.
has a financial relationship (Grant Or Contract) with Celegene;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Novartis;.

Julio Chavez, MD, MS

has a financial relationship (Other) with Allogene;.
has a financial relationship (Other) with GenMab;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Other) with ADC Therapeutics;.
has a financial relationship (Other) with BMS/Celgene;.
has a financial relationship (Grant Or Contract) with Jannsen;.
has a financial relationship (Other) with Lilly;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Other) with Beigene;.
has a financial relationship (Other) with Kite;.

Matthew Cortese, MD, MPH

has a financial relationship (Professional Services) with Abbvie, Inc.;.
has a financial relationship (Professional Services) with Secura Bio, Inc;.
has a financial relationship (Professional Services) with Precision Oncology;.
has a financial relationship (Professional Services) with Curio Life Sciences;.
has a financial relationship (Professional Services) with ADC Therapeutics, Inc;.
has a financial relationship (Professional Services) with Synthekine;.
has a financial relationship (Professional Services) with Astra Zeneca, Inc;.
has a financial relationship (Professional Services) with Cellectar Biosciences;.

Narendranath Epperla, MD, MS

has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Beigene;.
has a financial relationship (Other) with ADC Therapeutics;.
has a financial relationship (Other) with Lilly;.
has a financial relationship (Other) with Beigene;.

Steven Green

has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Sobi;.

Elizabeth Griffiths

has a financial relationship (Independent contractor) with Takeda Oncology;.
has a financial relationship (Grant Or Contract) with Celldex Therapeutics;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Takeda Oncology;.
has a financial relationship (Grant Or Contract) with Blueprint Medicines;.
has a financial relationship (Grant Or Contract) with NextCure Therapeutics;.
has a financial relationship (Independent contractor) with AstraZeneca Rare Disease;.
has a financial relationship (Grant Or Contract) with Astex Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Genentech, Inc;.
has a financial relationship (Independent contractor) with Apellis;.
has a financial relationship (Independent contractor) with CTI Biopharma;.
has a financial relationship (Grant Or Contract) with Alexion Pharmacueticals;.
has a financial relationship (Grant Or Contract) with Celgene/BMS;.
has a financial relationship (Independent contractor) with Alexion Pharmaceuticals;.
has a financial relationship (Independent contractor) with Novartis;.

Hamza Hassan

has no relevant financial relationships to disclose at this time.

Francisco Hernandez-Ilizaliturri, MD

has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with BioGene;.
has a financial relationship (Professional Services) with Cellectar;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with BMS/Celgene;.
has a financial relationship (Professional Services) with Incyte/Morphosys;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with ADC Therapuetics;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Epyzine;.

Kara Kelly

has a financial relationship (Professional Services) with Seagen;.

Alok Khorana

has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Sanofi-Aventis;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Anthos;.

David Kroll, MD, FACLP

has no relevant financial relationships to disclose at this time.

Alex Niu

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

Matthew Cortese, MD, MPH

has a financial relationship (Professional Services) with Abbvie, Inc.;.
has a financial relationship (Professional Services) with Secura Bio, Inc;.
has a financial relationship (Professional Services) with Curio Life Sciences;.
has a financial relationship (Professional Services) with Precision Oncology;.
has a financial relationship (Professional Services) with ADC Therapeutics, Inc;.
has a financial relationship (Professional Services) with Synthekine;.
has a financial relationship (Professional Services) with Astra Zeneca, Inc;.
has a financial relationship (Professional Services) with Cellectar Biosciences;.

Francisco Hernandez-Ilizaliturri, MD

has a financial relationship (Professional Services) with BioGene;.
has a financial relationship (Professional Services) with Cellectar;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with BMS/Celgene;.
has a financial relationship (Professional Services) with Incyte/Morphosys;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with ADC Therapuetics;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Epyzine;.
has a financial relationship (Professional Services) with Novartis;.
Moderator(s)

Matthew Cortese, MD, MPH

has a financial relationship (Professional Services) with Abbvie, Inc.;.
has a financial relationship (Professional Services) with Secura Bio, Inc;.
has a financial relationship (Professional Services) with Precision Oncology;.
has a financial relationship (Professional Services) with Curio Life Sciences;.
has a financial relationship (Professional Services) with ADC Therapeutics, Inc;.
has a financial relationship (Professional Services) with Synthekine;.
has a financial relationship (Professional Services) with Astra Zeneca, Inc;.
has a financial relationship (Professional Services) with Cellectar Biosciences;.

Francisco Hernandez-Ilizaliturri, MD

has a financial relationship (Professional Services) with BioGene;.
has a financial relationship (Professional Services) with Cellectar;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with BMS/Celgene;.
has a financial relationship (Professional Services) with Incyte/Morphosys;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with ADC Therapuetics;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Epyzine;.
has a financial relationship (Professional Services) with Novartis;.

Commercial Support Acknowledgement

This activity is supported with an independent medical education grant from Lilly USA, LLC.

Available Credit

  • 14.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 14.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 14.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 14.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 14.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 14.50 Contact Hours.

If you are interested in exhibiting at this meeting, please email sponsorships@binayfoundation.org.

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.